These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 30696910)

  • 1. Imaging endogenous macrophage iron deposits reveals a metabolic biomarker of polarized tumor macrophage infiltration and response to CSF1R breast cancer immunotherapy.
    Leftin A; Ben-Chetrit N; Joyce JA; Koutcher JA
    Sci Rep; 2019 Jan; 9(1):857. PubMed ID: 30696910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron imaging reveals tumor and metastasis macrophage hemosiderin deposits in breast cancer.
    Leftin A; Ben-Chetrit N; Klemm F; Joyce JA; Koutcher JA
    PLoS One; 2017; 12(9):e0184765. PubMed ID: 28898277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of Nanoparticle Enhancement in Polarized Breast Tumor Macrophage Deposits by Spatial Analysis of MRI and Histological Iron Contrast Using Computer Vision.
    Leftin A; Koutcher JA
    Contrast Media Mol Imaging; 2018; 2018():3526438. PubMed ID: 30510494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment.
    O'Brien SA; Orf J; Skrzypczynska KM; Tan H; Kim J; DeVoss J; Belmontes B; Egen JG
    Cancer Immunol Immunother; 2021 Aug; 70(8):2401-2410. PubMed ID: 33511454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron deposition is associated with differential macrophage infiltration and therapeutic response to iron chelation in prostate cancer.
    Leftin A; Zhao H; Turkekul M; de Stanchina E; Manova K; Koutcher JA
    Sci Rep; 2017 Sep; 7(1):11632. PubMed ID: 28912459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target delivery selective CSF-1R inhibitor to tumor-associated macrophages via erythrocyte-cancer cell hybrid membrane camouflaged pH-responsive copolymer micelle for cancer immunotherapy.
    Wang Y; Luan Z; Zhao C; Bai C; Yang K
    Eur J Pharm Sci; 2020 Jan; 142():105136. PubMed ID: 31704343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy.
    Ramesh A; Brouillard A; Kumar S; Nandi D; Kulkarni A
    Biomaterials; 2020 Jan; 227():119559. PubMed ID: 31670078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
    Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
    Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
    Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
    ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment.
    Wen J; Wang S; Guo R; Liu D
    Eur J Med Chem; 2023 Jan; 245(Pt 1):114884. PubMed ID: 36335744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.
    Cannarile MA; Weisser M; Jacob W; Jegg AM; Ries CH; Rüttinger D
    J Immunother Cancer; 2017 Jul; 5(1):53. PubMed ID: 28716061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging.
    Cuccarese MF; Dubach JM; Pfirschke C; Engblom C; Garris C; Miller MA; Pittet MJ; Weissleder R
    Nat Commun; 2017 Feb; 8():14293. PubMed ID: 28176769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The c.1085A>G Genetic Variant of
    Yeh YM; Hsu SJ; Lin PC; Hsu KF; Wu PY; Su WC; Chang JY; Shen MR
    Clin Cancer Res; 2017 Oct; 23(20):6021-6030. PubMed ID: 28724665
    [No Abstract]   [Full Text] [Related]  

  • 14. A Spatio-Temporal Model of Macrophage-Mediated Drug Resistance in Glioma Immunotherapy.
    Zheng Y; Bao J; Zhao Q; Zhou T; Sun X
    Mol Cancer Ther; 2018 Apr; 17(4):814-824. PubMed ID: 29440290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia promotes glioma-associated macrophage infiltration via periostin and subsequent M2 polarization by upregulating TGF-beta and M-CSFR.
    Guo X; Xue H; Shao Q; Wang J; Guo X; Chen X; Zhang J; Xu S; Li T; Zhang P; Gao X; Qiu W; Liu Q; Li G
    Oncotarget; 2016 Dec; 7(49):80521-80542. PubMed ID: 27602954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetism-mediated targeting hyperthermia-immunotherapy in "cold" tumor with CSF1R inhibitor.
    Fang Y; He Y; Wu C; Zhang M; Gu Z; Zhang J; Liu E; Xu Q; Asrorov AM; Huang Y
    Theranostics; 2021; 11(14):6860-6872. PubMed ID: 34093858
    [No Abstract]   [Full Text] [Related]  

  • 17. CSF1R- and SHP2-Inhibitor-Loaded Nanoparticles Enhance Cytotoxic Activity and Phagocytosis in Tumor-Associated Macrophages.
    Ramesh A; Kumar S; Nandi D; Kulkarni A
    Adv Mater; 2019 Dec; 31(51):e1904364. PubMed ID: 31659802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An
    Mason CA; Kossatz S; Carter LM; Pirovano G; Brand C; Guru N; Pérez-Medina C; Lewis JS; Mulder WJM; Reiner T
    J Nucl Med; 2020 Mar; 61(3):433-436. PubMed ID: 31420495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages.
    Zhang P; Zhao S; Wu C; Li J; Li Z; Wen C; Hu S; An G; Meng H; Zhang X; Yang L
    Immunotherapy; 2018 Aug; 10(11):935-949. PubMed ID: 30149762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients.
    Liu H; Wang J; Zhang M; Xuan Q; Wang Z; Lian X; Zhang Q
    Breast Cancer Res Treat; 2017 Nov; 166(1):95-107. PubMed ID: 28730338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.